2026-04-17T07:40:35Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1847302025-11-20T15:05:24Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Pérez de Llano, Luis A. author Dacal Rivas, David author Marina Malanda, Nuria author Plaza Moral, Vicente author Gullón Blanco, José Antonio author Muñoz Esquerre, Mariana author García Moguel, Ismael author Díaz Campos, Rocío M. author Martínez Moragón, Eva author Harbenau Mena, Alicia author Cosío, Borja G. author Padilla Galo, Alicia author Cisneros Serrano, Carolina author 2022-04-07T10:57:28Z 2022-04-07T10:57:28Z 2022-03-01 2022-04-07T09:41:39Z Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of controlled patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients. Asma Malalties pulmonars obstructives cròniques Utilització de medicaments Asthma Chronic obstructive pulmonary diseases Drug utilization The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma–COPD Overlap Syndrome